Comparative Pharmacology
Head-to-head clinical analysis: CLONIDINE HYDROCHLORIDE versus IOPIDINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLONIDINE HYDROCHLORIDE versus IOPIDINE.
CLONIDINE HYDROCHLORIDE vs IOPIDINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alpha-2 adrenergic agonist; centrally acting antihypertensive that reduces sympathetic outflow from the CNS, decreasing peripheral resistance, heart rate, and blood pressure.
Alpha-2 adrenergic agonist; reduces intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow.
Initial 0.1 mg orally twice daily; maintenance 0.2-0.6 mg/day in divided doses; maximum 2.4 mg/day. Also available as transdermal patch: 0.1-0.3 mg/day applied every 7 days.
Adults: 1 drop of 0.5% or 1% ophthalmic solution in the affected eye(s) three times daily, beginning 48 hours prior to surgery and continuing on the day of surgery. Alternatively, for intraocular surgery, 1 drop of 1% solution is administered 1 hour before surgery and 1 drop immediately after surgery.
None Documented
None Documented
Terminal half-life: 12-16 hours (range 6-20 hours); prolonged in renal impairment (up to 40 hours).
0.5-2 hours (terminal) for topical ophthalmic administration; clinical effect may persist longer due to local tissue binding.
Renal: 40-60% unchanged; hepatic metabolism to inactive metabolites (about 50%); fecal: minimal (<5%).
Renal excretion (% unchanged drug not determined; metabolites excreted renally)
Category A/B
Category C
Alpha-2 Agonist
Alpha-2 Agonist